I recently reported on Sanofi-Aventis’ decision to pull rimonabant from EU shelves. Since then, S-A has stoppedall rimonabant clinical development.
I also told you that clinical success of Pfizer’s Phase 3 CB1 antagonist, CP-945,598, seemed dubious. Yesterday, Pfizer pulled the plug on their drug, citing “changing regulatory perspectives on the risk/benefit profile of the CB1 class [...]
As you have likely already read, Pfizer has recently prioritized its portfolio and will nix discovery and early clinical development for drugs in several disease areas, including dyslipidemia/atherosclerosis, osteoporosis and osteoarthritis, and obesity independent of diabetes.
You might be wondering why the world’s largest pharmaceutical company is abandoning treatments for some of the West’s most common chronic medical problems. I [...]
ASBMR was eventful this year, with PMP osteoporosis trial news from several companies, most notably fracture data from Amgen’s denosumab and comparative BMD data from Merck’s odanacatib.
Of course, it’s easy enough for you to learn about these presentations from other news sources, so I won’t spend much time on them. Here’s the gist: Denosumab, the [...]
I am always on the prowl for, and rarely find, truly new management ideas that can be applied to drug R&D. Usually, ideas held out as new really aren’t, they’re just rehashed ideas, sometimes supported by new evidence. Sometimes, though, used ideas that are stated well and in new ways can be just as valuable.
Take the September [...]
A new crop of mega-pharma leaders has been installed recently, so it’s no surprise that they’re making rounds among analysts and reporters, telling anyone who will listen that they’ve seen the errors of their forebears’ ways and are committed to do things differently and better now. Chief among their messages is that they will tackle [...]
